Novartis AG vs Solaredge Technologies Inc — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while Solaredge Technologies Inc trades at $32.08 (market cap $2.00B). The key difference: Novartis AG is far larger — about 134.3× Solaredge Technologies Inc's market cap, and Novartis AG pays a 3.31% dividend while Solaredge Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Solaredge Technologies Inc for 34 Days on average.
| NVS | SEDG | |
|---|---|---|
Market Cap | $268.57B | $2.00B |
Volume | 1,532,573 | 2,739,860 |
Sector | Health | Energy |
52-Week High | $168.62 | $78.51 |
52-Week Low | $121.80 | $28.47 |
Typical Hold Time | 82 Days | 34 Days |
Enterprise Value | $309.89B | $1.86B |
Dividend Yield | 3.31% | — |
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
SolarEdge Technologies (SEDG) trades at $32.21, down 2.86% on the day, amid a bearish technical signal and mixed earnings performance. The company reported a net loss of $405.45M in 2025, with negative profit margins, though revenue grew to $1.18B. Recent news highlights legal investigations and volatility driven by solar sector pressures and new AI data center initiatives announced in September 2026.
The outlook remains cautious due to persistent losses and high debt, but analyst consensus suggests moderate upside to a $37.75 price target. Key risks include ongoing legal scrutiny, competitive pressures, and reliance on solar market recovery. Investment appeal hinges on execution of growth targets and margin improvement.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →